Form D · Pharmaceuticals
Laurentide Therapeutics Inc.
Atlanta, GA · CIK 0002157396
Offering snapshot reported Sep 28, 2026 · SEC filing
- Reported sold
- $100K Offering amount: $100K
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 20, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 28, 2026 | Initial | $99,999 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-599035
Source: Form D, filed Sep 28, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Horace Nalle | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
2525 Peachtree Rd #27
Atlanta, GA, 30305-3668
Phone: 4046801486
Atlanta, GA, 30305-3668
Phone: 4046801486